Subsequent Event

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Event

NOTE 14. SUBSEQUENT EVENT

On April 28, 2016, the Company confirmed that it had received an unsolicited, non-binding proposal from Sanofi to acquire all outstanding shares of Medivation common stock for $52.50 in cash, which followed a private letter received by the Company from Sanofi on April 15, 2016. On April 29, 2016, the Company announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from Sanofi to acquire Medivation for $52.50 per share in cash substantially undervalues Medivation and is not in the best interests of the Company and its stockholders.